Activation of NGF signaling pathway limits the response of lenvatinib in hepatocellular carcinoma

Key Points

• The study aims to explore how the NGF signaling pathway contributes to resistance against lenvatinib in hepatocellular carcinoma.
• Identification of NGF associated signaling axis
• Assessment of lenvatinib resistance mechanisms
• Evaluation of TrkA inhibition as a therapeutic intervention
• NGF signaling was found to drive resistance to lenvatinib in HCC.
• TrkA inhibition showed potential in overcoming this resistance.
• These findings contribute to understanding TKI resistance in non-neural tumors.